- Home
- IPDN vs RNAZ Comparison
IPDN vs RNAZ Comparison
Compare IPDN & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPDN
- RNAZ
- Stock Information
- Founded
- IPDN 2003
- RNAZ 2016
- Country
- IPDN United States
- RNAZ United States
- Employees
- IPDN N/A
- RNAZ N/A
- Industry
- IPDN EDP Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- IPDN Technology
- RNAZ Health Care
- Exchange
- IPDN Nasdaq
- RNAZ Nasdaq
- Market Cap
- IPDN 5.2M
- RNAZ 6.1M
- IPO Year
- IPDN 2013
- RNAZ 2021
- Fundamental
- Price
- IPDN $2.83
- RNAZ $11.60
- Analyst Decision
- IPDN
- RNAZ Strong Buy
- Analyst Count
- IPDN 0
- RNAZ 1
- Target Price
- IPDN N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- IPDN 17.3M
- RNAZ 11.2K
- Earning Date
- IPDN 11-13-2025
- RNAZ 11-13-2025
- Dividend Yield
- IPDN N/A
- RNAZ N/A
- EPS Growth
- IPDN N/A
- RNAZ N/A
- EPS
- IPDN N/A
- RNAZ N/A
- Revenue
- IPDN $6,459,379.00
- RNAZ N/A
- Revenue This Year
- IPDN N/A
- RNAZ N/A
- Revenue Next Year
- IPDN N/A
- RNAZ N/A
- P/E Ratio
- IPDN N/A
- RNAZ N/A
- Revenue Growth
- IPDN N/A
- RNAZ N/A
- 52 Week Low
- IPDN $0.97
- RNAZ $6.15
- 52 Week High
- IPDN $12.39
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- IPDN 46.16
- RNAZ 53.39
- Support Level
- IPDN $2.63
- RNAZ N/A
- Resistance Level
- IPDN $12.39
- RNAZ $11.45
- Average True Range (ATR)
- IPDN 1.79
- RNAZ 0.54
- MACD
- IPDN -0.33
- RNAZ -0.31
- Stochastic Oscillator
- IPDN 8.91
- RNAZ 99.08
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates majority of its revenue from TalentAlly Network Segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.